Neoantigenics, Inc. logo

Neoantigenics, Inc.

Neoantigenics, is developing oncology theranostics (therapeutic plus diagnostic) products, based on oocyte (egg)-associated cancer neoantigens uniquely expressed on a wide range of urogenital tract cancers _ ovarian, uterine, bladder and renal cancers.

Neoantigenics, licensed discoveries made by Dr. John Herr at the University of Virginia School of Medicine on the several proteines, which are present on oocyte (neoantigens) and are also expressed on the surface of cells of aggressive-stage tumors.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://neoantigenics.com
Founded2012
Disease Focus
Development Stage
STOCK CODENon Listed
Address
1000 Research Park Boulevard Suite 103,VA 22911
Charlottesville
United States
Email
Contact Number
+1 434-984-9723

In Jan 2014, Neoantigenics entered into an early stage R&D collaboration with Pfizer, for the development of antibody-based therapeutics and companion diagnostics targeting Neoantigenics proprietary oocyte-associated biomarkers, which are selectively expressed on a wide array of human cancers.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/neoantigenics-inc.” connections=”true” suffix=””]

In 2014, Pfizer made an equity investment in Neoantigenics through the Pfizer Seed Fund. Beside this it received investment from the Center for Innovative Technologys GAP Fund and an award from the Commonwealth Research Commercialization Fund.